The Odyssey of an Orphan Device – Eclipse Regenesis’ Short Bowel Syndrome Solution
Andre Bessette

Date(s) – 09/10/19
6:00 pm – 9:00 pm

Event Description:
Eclipse Regenesis, Inc. is developing the first restorative therapy to address pediatric and adult Short Bowel Syndrome (SBS), a malabsorption disorder caused by a lack of functional small intestine. Current chronic therapies for SBS include expensive medication and intestinal surgery, which come at a staggering average 5-year cost of $1.6M per patient. Via distraction enterogenesis, the Eclipse XL1 System is able to harness the body’s own tissue regenerative capabilities to produce new, fully functional intestine in vivo. The Eclipse XL1 is the first device based solution for SBS, which is a rare orphan disease market that has been dominated by biotech. From it’s birth in a lab at UCLA to incubation at Stanford and now final emergence as a Bay Area start up, Eclipse’s odyssey touches on many of the current medtech industry challenges of getting a surgeon’s brilliant idea translated into clinical reality to address a syndrome that has no solution today.

Event Speaker Bio:

Andre Bessette, CEO, Eclipse Regenesis, Inc.

Andre Bessette has over 20 years of medical device industry experience with a broad range of applications including orthopedics, sports medicine, oncology, general surgery, plastic surgery, cardiology, pain management, and ENT. He has held various leadership positions in engineering, operations, finance, clinical, sales and marketing throughout his career. Currently, he is Co-Founder and Chief Executive Officer of Eclipse Regenesis, Inc. based in Menlo Park, CA. Prior to Eclipse, he was the Chief Commercial Officer and Executive Vice President for Vantage Surgical Systems. Vantage was an early stage development company focused on a novel minimally invasive robotic surgical systems. Before that, he was Vice President of Marketing for SentreHEART, Inc. which is focused on the development of the first catheter based solution for left atrial appendage closure. From 2006 to 2011, he was the Vice President of Marketing, Clinical Affairs, and International Business at PEAK Surgical, Inc. PEAK was focused on the development and commercialization of an advanced energy surgical platform for multiple surgical specialties. He was part of the original management team that took PEAK from inception (2006) all the way to acquisition by Medtronic, Inc. in 2011. Prior to PEAK, he worked at ArthroCare Corporation (now SNN) in various marketing and international management roles.